Literature DB >> 24557435

Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study.

Chien-Hsing Lu1, I-Hui Chen, Yi-Jen Chen, Kung-Liahng Wang, Jian-Tai Timothy Qiu, Hao Lin, Wu-Chou Lin, Wen-Shiung Liou, Yu-Fang Huang, Yue-Shan Lin, Yi-Torng Tee, Yao-Ching Hung.   

Abstract

OBJECTIVE: This study aimed to determine the clinical prognostic factors involved in carcinosarcoma of the ovary, fallopian tube, and peritoneum.
MATERIALS AND METHODS: This retrospective study was undertaken by the Taiwanese Gynecologic Oncology Group. The retrieved clinical data included demographic characteristics, medical disease, tumor status, extent of surgery, and adjuvant chemotherapy.
RESULTS: In total, 63 patients with carcinosarcoma of the ovary, fallopian tube, and peritoneum were identified. Sixty-one patients with complete data were enrolled for further data analysis. The mean follow-up period was 1.0 year, and the mean overall survival was 15.4 months. By log-rank tests, age, menopausal status, parity, hypertension, diabetes, primary tumor size, para-aortic lymph node metastasis, pretreatment CA-125, preceding diagnostic surgery, hysterectomy, lymphadenectomy, other surgeries, and paclitaxel use were not predictive of overall survival.Omentectomy, no gross residual implants after surgery, platinum treatment, and no pelvic lymph node metastasis had a trend toward better survival. Early diagnosis at stage I and cisplatin/ifosfamide regimen were significant associated with a better overall survival in log-rank and simple Cox regression tests. Bilateral ovarian tumors and metastatic tumors larger than 2 cm were significantly associated with a poorer overall survival.
CONCLUSIONS: Early diagnosis at stage I, unilateral ovarian tumor, metastatic tumors less than 2 cm, and cisplatin/ifosfamide regimen were predictive of a better survival.Omentectomy and complete debulking surgery also showed a trend toward better survival. Thus, these treatment strategies should be applied in patients with carcinosarcoma of the ovary, fallopian tube, and peritoneum.

Entities:  

Mesh:

Year:  2014        PMID: 24557435     DOI: 10.1097/IGC.0000000000000083

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

Review 2.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

3.  Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.

Authors:  Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

4.  Primary peritoneal carcinosarcoma arising from the Douglas pouch: A case report.

Authors:  Takahiro Koyanagi; Yoko To; Miho Ando; Sakiko Matsuoka; Sumie Nakamura; Maki Goto; Haruhiko Kondo; Fuyuki Eguchi; Hiroshi Tsujioka
Journal:  Mol Clin Oncol       Date:  2018-09-04

5.  Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma.

Authors:  Wen-Peng Wang; Ning Li; Yuan-Yuan Zhang; Yu-Tao Gao; Yang-Chun Sun; Li Ge; Ling-Ying Wu
Journal:  Cancer Manag Res       Date:  2018-07-10       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.